CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

Simple Summary The CD137 receptor is expressed by activated antigen-specific T-cells. CD137(+) T-cells were identified inside TILs and PBMCs of different tumor types and have proven to be the naturally occurring antitumor effector cells, capable of expressing a wide variability in terms of TCR specificity against both shared and neoantigenic tumor-derived peptides. The aim of this review is thus summarizing and highlighting their role as drivers of patients' immune responses in anticancer therapies as well as their potential role in future and current strategies of immunotherapy. The CD137 receptor (4-1BB, TNF RSF9) is an activation induced molecule expressed by antigen-specific T-cells. The engagement with its ligand, CD137L, is capable of increasing T-cell survival, proliferation, and cytokine production. This allowed to identify the CD137(+) T-cells as the real tumor-specific activated T-cell population. In fact, these cells express various TCRs that are specific for a wide range of tumor-derived peptides, both shared and neoantigenic ones. Moreover, their prevalence in sites close to the tumor and their unicity in killing cancer cells both in vitro and in vivo, raised particular interest in studying their potential role in different strategies of immunotherapy. They indeed showed to be a reliable marker able to predict patient's outcome to immune-based therapies as well as monitor their response. In addition, the possibility of isolating and expanding this population, turned promising in order to generate effector antitumor T-cells in the context of adoptive T-cell therapies. CD137-targeting monoclonal antibodies have already shown their antitumor efficacy in cancer patients and a number of clinical trials are thus ongoing to test their possible introduction in different combination approaches of immunotherapy. Finally, the intracellular domain of the CD137 receptor was introduced in the anti-CD19 CAR-T cells that were approved by FDA for the treatment of pediatric B-cell leukemia and refractory B-cell lymphoma.

Automated summary

The CD137 receptor, expressed by activated antigen-specific T-cells, plays a crucial role in driving immune responses against cancer. CD137(+) T-cells, capable of recognizing a wide range of tumor-derived peptides, have shown efficacy in killing cancer cells both in vitro and in vivo, making them a promising candidate for immunotherapy strategies. CD137-targeting monoclonal antibodies have demonstrated antitumor efficacy in cancer patients, with ongoing clinical trials to explore their potential in combination approaches of immunotherapy. Additionally, the intracellular domain of the CD137 receptor has been incorporated into anti-CD19 CAR-T cells approved for treating pediatric B-cell leukemia and refractory B-cell lymphoma.